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Objective. The aim of this study was to determine if vaginal application of the immune response modiﬁer imiquimod (Aldara
cream, 3M Pharmaceuticals, St Paul, Minn) would alter the course and/or outcome of female genital tract infection with a human
isolate of Chlamydia trachomatis in a murine model. Methods. Groups of CF-1 mice were treated with Aldara on three diﬀerent
schedules: (1) ongoing beginning 5 days prior to and continuing through day 5 of infection; (2) a single prophylactic dose 2 hours
prior to infection; and (3) therapeutic from day 4 to day 14 of infection. Mice were infected vaginally with a serovar D strain
of Ct r a c h o m a t i s , and monitored by culture to determine the level of shedding and duration of infection. Results. We observed a
signiﬁcant reduction in both duration of infection and the level of shedding during the acute phase in mice treated on an ongoing
basis commencing 5 days prior to infection. There was no eﬀect with respect to the other regimens. Conclusion. These results
demonstrate that ongoing Aldara treatment has eﬃcacy and may enhance local innate immunity which reduces the duration of
subsequent infection with human isolates of Ct r a c h o m a t i sin a murine model of female genital tract infection.
Copyright © 2006 Joseph M. Lyons et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Imiquimod is an immune response modiﬁer [1] that un-
der the trade name of Aldara (3M Pharmaceuticals, St
Paul, Minn) has FDA approval for the external treatment of
anogenital warts. In addition to this highly eﬀective appli-
cation [2], imiquimod has been shown to be eﬀective in an
increasing number of dermatological conditions, including
common warts, actinic keratoses, and basal cell carcinomas,
as well as lentigo malina and molluscum contagiosum [3].
In two other infectious diseases with cutaneous manifesta-
tions, genital herpes and leishmaniasis, it has demonstrated
signiﬁcant eﬃcacy in animal models [4, 5], although results
in humans have been equivocal [6–9]. In all of these set-
tings, imiquimod is thought to act by binding independently
to toll-like receptors (TLR)-7 and TLR-8 and activating the
signal transduction cascade that triggers transcription factor
NK-kB, which in turn upregulates production of cytokines
and chemokines that direct a sustained TH1 dominant cellu-
l a ri m m u n er e s p o n s e[ 10–12]. Both TLR-7 and TLR-8 have
been shown to be expressed on both human and mouse cells
[13], making mouse models of human disease useful tools in
the assessment of the treatment potential of imiquimod in
those settings where such models exist.
Chlamydia trachomatis is the most prevalent sexually
transmitted bacterial pathogen in the world, with an esti-
mated 89 million new cases occurring each year [14]. The
signiﬁcant morbidity associated with the severe sequelae of
Ct r a c h o m a t i sgenital tract infection in women has driven
eﬀorts to both control the spread of and to eﬀectively treat
those infected with this human pathogen. Although highly
eﬀective antibiotics are available [15, 16], the incidence has
been on the increase since the mid 1990s [14], and despite
considerable eﬀorts over the last 20 years, no vaccine can-
didates have emerged. It is generally accepted that the im-
mune responses made during persistent and recurrent infec-
tionscontributetotheimmunopathicnatureoftheseverese-
quelae, which includes pelvic inﬂammatory disease, tubal in-
fertility, and ectopic pregnancy [17–20]. While on the other
hand, TH1 dominant immune responses have been shown
to play a role in controlling the spread of infection within
the genital tract and to provide some level of acquired im-
munity as evidenced by reduced shedding of infectious units
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Taken together, these facts make the use of immune modula-
tors that enhance local TH1 dominant responses an appeal-
ing approach to prophylacticly and/or therapeutically treat C
trachomatis female genital tract infection.
Much of our understanding of Ct r a c h o m a t i sfemale gen-
ital tract infection has been derived from the use of a murine
model of noninvasive lower genital tract infection developed
by Tuﬀrey and Taylor-Robinson [22]. In our laboratory, we
use this model and routinely infect mice with chlamydial
strains belonging to the oculogenital biovar of Ct r a c h o m a -
tis (serovars D-K), which results in an infection that in most
of its features closely mimics human infection, both in its
course and outcome [23]. Using this model, we assessed the
eﬃcacy of imiquimod to alter the course of infection under
three diﬀerent vaginal application schedules: (1) ongoing be-
ginning 5 days prior to and continuing through day 5 of in-
fection; (2) a single prophylactic dose 2 hours prior to infec-
tion; and (3) therapeutic from day 4 to day 14 of infection.
Eﬃcacy was evaluated by comparing the susceptibility to in-
fection, the level of shedding, and the duration of infection
between imiquimod- and placebo-treated groups of mice.
MATERIALS AND METHODS
Murinemodel
Female CF-1 mice were purchased from Charles River Lab-
oratories (Wilmigton, Mass) and were used at 7-8 weeks of
age. In order to interrupt the normal 4-5 day estrous cy-
cle and induce prolonged diestrous and thus enhance the
initial infection rate, progesterone in the form of medrox-
yprogesterone acetate (Depo-Proveva, Pharmacia & Upjohn
Co Peapeck, NJ), was administered subcutaneously in 2.5mg
doses, 10 and3daysprior to infection[22,23].Micewerein-
oculatedintravaginallybydirectinstillationof10μLofCtr a-
chomatis (serovar D) bacterial suspension containing 1×105
inclusion forming units (IFU). The human Ct r a c h o m a t i s
serovar D genital isolate was propagated, titrated, and iso-
lated in cycloheximide-treated McCoy cell monolayers using
standard techniques [24]. All experiments were conducted
in a BL-2 containment facility in compliance with animal
care regulations and under protocols approved by the Insti-
tutional Research Animal Care Committee.
Imiquimodtreatment
On the days prior to (−) and/or after (+) infection as indi-
cated in the results table, 10uL of Aldara diluted 1 : 4 in
salineoraplacebosimilarincompositiontotheinactivebase
used in Aldara was administered intravaginally. The follow-
ing Aldara regimens were tested: (1) Aldara or base at days
−5, −3, −1, +1, +3, +5; (2) Aldara or base at days +4, +6,
+8, +10, +12, +14; (3) Aldara or base 2 hours prior to infec-
tion; and (4) neither Aldara nor base.
Infectionmonitoring
The presence of Chlamydia in the lower genital tract was de-
termined by culturing the material obtained by swabbing the
vaginal vault and ectocervix with a dacron-tipped swab that
wasstoredat −70◦Cin2-SPAtransportmediumuntiltested.
Specimens were plated onto McCoy monolayers in duplicate
microtiter plates, centrifuged, and incubated at 37◦Cf o r7 2
hours. One plate was then ﬁxed, stained with iodine and in-
clusions were enumerated (actual IFU counts in table), while
theotherplatewasstoredat −70◦Candusedtoverifythesta-
tus of primary culture negative specimens. A specimen was
considered culture positive if inclusions were observed in ei-
ther primary or secondary culture.
Statisticanalysis
Thedurationofinfectionbetweengroupswasanalyzedusing
the Wilcoxon rank sum test.
RESULTS
As displayed in Table 1, we observed a statistically signiﬁcant
reductioninthemediandurationofinfectioninmicetreated
on multiple occasions prior to and during the acute phase of
Ct r a c h o m a t i sinfection, 4 days for imiquimod-treated ani-
mals as compared to 19 days for the placebo group (P<. 05).
Remarkably, although no eﬀect was observed on the inci-
dence of infection, there was a suggestion that the number
of IFU shed during the ﬁrst round of intracellular replication
(day 2) was reduced when compared to the placebo group.
This is especially marked when the average number of IFU
shed by treated mice with a duration of infection less than
or equal to the median duration of the group is compared to
the average number of IFU shed by the placebo group on day
2, 224 IFU versus 2010 IFU, respectively. By day 4 the dif-
ferences between the ongoing treatment group and placebo
group were unequivocal, with 6 of 8 treated mice being cul-
ture negative in primary culture while all four placebo con-
trol mice were primary culture positive.
Following the discontinuation of imiquimod treatment
on day 5 postinfection, 5 of 8 treated mice were culture nega-
tive for the duration of the study period, while the remaining
3 mice in this group had shedding patterns and durations of
infection similar to placebo mice.
The other regimens assessed, a single prophylactic ap-
plication 2 hours prior to infection (data not shown) and
a 6-application therapeutic regimen commencing on day 4
postinfection, had neither a positive nor negative eﬀect on
either the duration of infection or the pattern of shedding
during infection.
DISCUSSION
Ramsey and colleagues [25] recently reported in this journal
that imiquimod had no eﬃcacy in modifying the susceptibil-
itytoorcourseofinfectionwiththemousepneumonitisbio-
var (MoPn) of Chlamydia when administered either orally
or intravaginally in essentially the same murine model of C
trachomatis female genital tract infection used in the present
study. In that study, imiquimod was administered to groups
of inbred BALB/c mice either orally on ﬁve occasions (3 daysJoseph M. Lyons et al 3
Table 1: The inﬂuence of multiple intravaginal application regimens on the course of Ct r a c h o m a t i sgenital tract infection.
Treatment Animal Culture results on indicated day postinfection∗
Duration Median Rank sum
group 2 4 7 10 14 17 21 24 28 35 42 49 53 60 63 67 duration P value
A3 170 + − − − −−−−−−−−−−− 4
4. 0 5
A4 10 − 540 3470 490 + −−−−−−−−−− 17
Prophylactic A5 310 + − − − −−−−−−−−−−− 4
imiquimod A6 140 − − − − −−−−−−−−−−− 2
−5,−3,−1, A15 100 − − − − −−−−−−−−−−− 2
+1,+3,+5 A16 11380 + 1060 7570 − −−−−−−−−−−− 10
A25 8610 990 1350 10 10 + + + + −−−−−−− 28
A0 400 10 − − − −−−−−−−−−−− 4
Placebo
−5,−3,−1,
+1,+3,+5
B1 870 380 15540 2370 + + ++++++− ++− 63
19 — B2 4980 300 1130 − − −−−−−−−−−−− 7
B3 1460 5490 32020 4850 50 + + + + −−−−−−− 28
B4 730 1670 23610 780 − −−−−−−−−−−− 10
E1 20 370 33590 90 10 + + −−−−−−−−− 21
E2 400 610 1210 10 + + ++++−−−−−− 35
Therapeutic E3 240 1030 5260 40 − −−−−−−−−−−− 10
imiquimod E4 1390 4740 2430 470 − +++++−−−−−− 35 35 Not signiﬁcant
+ 4 , + 6 , + 8 , E 5 1 6 0 5 0 2 0 + + +++++−−−−−− 35
+10,+12,+14 E6 270 220 8960 + + + + −−++−−−−− 42
E15 320 250 260 − − −−−−−−−−−−− 7
E0 4970 500 610 −− +++++−−−−−− 35
Placebo
+4,+6,+8,
+10,+12,+14
F2 320 10 60 30 − −−−−−−−−−−− 10
F4 8840 860 210 20 + + + + −−−−−−−− 24 26 —
F16 1270 1040 612 60 + + +++++−−−−− 42
F25 760 1730 19660 70 200 + + + + −−−−−−− 28
G1 + − − − − −−−−−−−−−−− 2
G2 1170 1290 990 + + + +++++++−−− 53
G3 30 10 11040 10 −− − −+ −−−−−−− 28
None G4 260 460 6010 20 − −−−−−−−−−−− 10 28 ∗∗
G5 700 610 4280 + 30 − +++−−−−−−− 28
G6 3350 5140 2194 −− − + −−−+ −−−−− 42
G14 810 420 341 10 − −−−−−−−−−−− 10
G25 1620 340 83 10 −− −+ − ++−−−−− 42
∗Mice were sampled every 2–7 days postinfection. Numerical values represent the number of IFU enumerated in primary culture through
day 14; +/− represents the presence (+) or absence (−) of inclusions upon secondary subculture.
∗∗Not diﬀerent from either placebo group.
prior to infection, on the day of infection, and 1, 3, and 6
days after infection), or intravaginally on four occasions (2
days prior to infection, and 1, 3, and 6 days after infection).
These authors concluded that although the results do not
hold promise for imiquimod in therapy for chlamydial infec-
tion,theeﬃcacyofimiquimodmayhavebeenmaskeddueto
the obvious potent TH1 response that naturally occurs dur-
ing genital tract infection with MoPn and/or that the TLR-
7 expression was absent or insuﬃcient within the gastroin-
testinal and genital tracts to allow a response to imiquimod.
We, on the other hand, observed a signiﬁcant reduction in
the median duration of infection and level of shedding in
outbred CF-1 mice treated intravaginally on six occasions (5,
3, and 1 days prior to infection and 1, 3, and 5 days after in-
fection) with a strain belonging to the oculogenital biovar of
Ct r a c h o m a t i s , the biovar that actually causes human disease.
Based on this result, we would conclude that TLR-7 and/or
TLR-8 is expressed in the female mouse genital tract, and
that imiquimod and/or immune modulators as a class might
have some, albeit limited, place in the therapy of chlamydial
infection. In a letter to the Editor, we questioned the utility
of MoPn to serve as a surrogate for the oculogenital biovar
and referenced our ﬁnding [26], the details of which form
the basis of this report.4 Infectious Diseases in Obstetrics and Gynecology
Although diﬀerences in the details of the two studies,
such as mouse strain and intravaginal application schedule,
couldexplainthecontraryresultsobtainedinthesetwostud-
ies, in our opinion the major diﬀerence in experimental de-
sign that contributed to the diﬀerent outcomes was the se-
lection of the biovar of Chlamydia against which to assess
the eﬃcacy of this potent immunomodulator. Multiple phe-
notypic diﬀerences that bear directly on the ability to detect
the potential infection and immunity altering eﬀects of im-
iquimod have been reported between C muridarum,M o P n ,
and the 11 diﬀerent serovars that comprise the human ocu-
logenital biovar of Ct r a c h o m a t i s[27]. Most notable among
these diﬀerences are those that arise from variability in both
the unique obligate intracellular developmental cycle [28]
and the degree of tryptophan auxotrophy [29] that exists
within the genus Chlamydia. Taken together, phenotypes as-
sociatedwiththesetwocharacteristicsofagivenstraindeﬁne
the extent to which interferon-gamma can exert a nutritional
inﬂuence on the chlamydial replication cycle via tryptophan
depletion following IDO induction. In the present context,
MoPn has been shown to be signiﬁcantly less sensitive to the
tryptophan depleting eﬀect of interferon-gamma when com-
pared in vitro to strains belonging to diﬀerent serovars of the
oculogenital biovar, including a strain identiﬁed as serovar D
[30]. In addition, the course and outcome of MoPn infection
inthefemalemousegenitaltractisessentiallyindependentof
interferon-gamma compared to infection with serovar D, as
evidenced by uncontrolled and invasive progression of dis-
ease during serovar D infection in interferon-gamma deﬁ-
cient mice compared to the controlled and contained course
seen in interferon-gamma suﬃcient mice [31, 32]. This lat-
ter diﬀerence between the biovars is likely to be a result of
a mechanism that involves basic elements of the TH1 innate
response that are induced by interferon-gamma, including
eventstriggeredinthehostcellbyIDO-mediatedtryptophan
depletion [33, 34], as well as events associated with the sig-
niﬁcantly more rapid replication and release kinetics char-
acteristic of the MoPn developmental cycle [28]. This latter
phenotypic diﬀerence might favor the escape of MoPn from
many of the immediate consequences of the potent TH1r e -
sponses that it induces, eﬀects that cannot be escaped by the
slower replicating strains of the oculogenital biovar.
Imiquimod is thought to exercise its antiviral, antitumor,
and antimicrobial activity through multiple pathways that
promote a TH1 dominant response that augments the cell-
mediated immune responses of both the innate and acquired
immune systems. This is achieved through the induction, via
TLR-7 and/or TLR-8, of an array of immune response modi-
ﬁers, most notably interferon-γ and tumor necrosis factor-α,
as well as interferon-α, G-CSF, GM-CSF, the interleukins, IL-
1, IL-2, IL-6, IL-8, and IL-12, and chemokines such as MIP-
1a, MIP-1b, and MCP-1 [1, 35]. In addition, imiquimod has
been shown to induce nitric oxide synthase, enhance anti-
gen presentation by dendritic cells [36], and most recently
to induce apoptosis [37]. Many of these elements of innate
and adaptive immunity have been independently assessed in
the murine model used in this study, and some have been
shown to play a role in the protective immunity that follows
infection [38]. However, much of this knowledge has been
obtainedusingMoPnasasurrogatemodelagentfortheocu-
logenital biovar that actually causes human disease. Unfor-
tunately, the translational value of much of this work may
be in question as a result of numerous diﬀerences that have
been recently reported between MoPn and the human biovar
[39]. Two of these diﬀerences were drawn upon to help ex-
plain the discrepancy between our results and those of Ram-
sey and colleagues, and other diﬀerences might also play a
role.
In conclusion, using the murine model of human female
genitaltractinfectionandincontrasttotheresultsofRamsey
and colleagues, we observed that intravaginally applied im-
iquimodsigniﬁcantlyreducedthemediandurationofgenital
tract infection with a human isolate of Ct r a c h o m a t i s . When
administeredonmultipleoccasions,dayspriortoandduring
the acute phase of infection, both the duration of infection
and the level of shedding in some mice were reduced, per-
haps through a mechanism of enhanced local innate immu-
nity.Understandingthemechanismofthisenhancedrespon-
siveness might provide insight into the complex immunobi-
ologyoffemalegenitaltractinfectionwithCtr achomatisand
may lead to new prevention and treatment methods. Also,
given that acquired protective immunity to Ct r a c h o m a t i s
shares many elements in common with the innate immune
responsesmadeduringinitialexposure[33],onemightspec-
ulatethatimiquimodcouldbeeﬀectiveinpreviouslyinfected
women by promoting an enhanced anemnestic response to
reinfection. It is also interesting to speculate if women us-
ingthemultipleapplicationregimenofimiquimodapproved
for the treatment of genital warts might realize an alteration
in the cytokine responsiveness within the genital tract and a
possible reduced risk of Ct r a c h o m a t i sgenital tract infection.
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